FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-02-25

Price

$14.34

-0.14%

Score13.5Top Tier

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

FOLD's 'Steady Climb' is a technical artifact of its pending acquisition by BioMarin (BMRN) for $14.50/share cash. The stock is pinned at $14.34 (1.1% spread), acting as a low-beta cash proxy rather than a growth vehicle. The recent Q4 earnings 'miss' was irrelevant to the thesis as the deal remains the primary driver, with the low volatility reflecting high market confidence in the transaction closing.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

MERGER ARB: Thesis is purely capturing the $0.16 spread to the $14.50 deal price (closing Q2 2026).
CATALYST WATCH: Shareholder vote on March 3, 2026, is the next procedural hurdle; approval is expected.
RISK PROFILE: Downside is the pre-deal price (~$10-$11) if the transaction breaks (Regulatory/FTC), though spreads imply >90% probability of success.

← Back to 2026-02-25 View Full FOLD History →Yahoo Finance &nearr;